Literature DB >> 26928727

Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial.

Vanessa Selak1, Matire Harwood2, C Raina Elley3, Chris Bullen4, Angela Wadham4, Varsha Parag4, Natasha Rafter5, Bruce Arroll3, Dale Bramley6, Sue Crengle7.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the consistency of the proportional effect of fixed-dose combination therapy (the 'polypill') on the use of recommended cardiovascular preventative medications among indigenous Māori and non-indigenous adults in New Zealand.
METHODS: We randomised Māori and non-Māori primary care patients at high risk of cardiovascular disease (either because of a prior event or with an estimated 5-year risk of a first event of at least 15%) to a polypill (containing aspirin, statin and two antihypertensives) or usual care for a minimum of 12 months. All patients had indications for all polypill components according to their general practitioner, and all medications (including the polypill) were prescribed by the patient's general practitioner and dispensed at community pharmacies. The main outcome for this study was the use of all recommended medications (antiplatelet, statin and two antihypertensives) at 12 months. Heterogeneity in the effect of polypill-based care compared with usual care on this outcome by ethnicity was assessed by logistic regression.
RESULTS: Baseline use of recommended medications was 36% (93/257) among Māori and 51% (130/156) among non-Māori participants. Polypill-based care was associated with an increase in the use of recommended medications among Māori (relative risk [RR]: 1.87; 95% confidence interval [CI]: 1.50-2.34) and non-Māori (RR: 1.66; 95% CI: 1.37-2.00) when compared with usual care at 12 months, and there was no statistically significant heterogeneity in this outcome by ethnicity (p = 0.92).
CONCLUSION: Polypill-based care is likely to reduce absolute inequities between Māori and non-Māori in the use of recommended cardiovascular preventative medications given baseline absolute differences and the consistency of the proportional effect of this intervention by ethnicity in this pragmatic trial in primary care. © The European Society of Cardiology 2016.

Entities:  

Keywords:  Cardiovascular diseases; ethnic groups; healthcare disparities; polypill; secondary prevention

Mesh:

Substances:

Year:  2016        PMID: 26928727     DOI: 10.1177/2047487316637196

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  3 in total

Review 1.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 2.  [Management of different cardiovascular risk factors with a combination tablet (polypill)].

Authors:  P Bramlage; W März; D Westermann; B Weisser; J H Wirtz; U Zeymer; P Baumgart; G van Mark; U Laufs; B K Krämer; T Unger
Journal:  Herz       Date:  2017-03-24       Impact factor: 1.443

Review 3.  Cardiovascular diseases in mega-countries: the challenges of the nutrition, physical activity and epidemiologic transitions, and the double burden of disease.

Authors:  Simon Barquera; Andrea Pedroza-Tobias; Catalina Medina
Journal:  Curr Opin Lipidol       Date:  2016-08       Impact factor: 4.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.